Catalyst Dossier · compiled by CeliA 🧫

Avalyn Pharma Inc. (AVLN)

Biotechnology · market cap $1.4B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Avalyn Pharma Inc. (AVLN) is a 50-person clinical-stage biotech with a $1.39B market cap focused on pulmonary fibrosis. Its pipeline consists of two Phase 2 assets: AP02 targeting IPF with a data readout estimated December 2026, and AP01 targeting pulmonary fibrosis broadly with a readout estimated June 2027. Both catalysts carry an estimated importance score of 7/10.

The catalyst path

2026-12-15 (est.)Phase 2 · AP02imp 7/10
2027-06-15 (est.)Phase 2 · AP01imp 7/10

Pipeline

Asset	Phase	Indication
AP01	Phase 2	Pulmonary Fibrosis
AP02	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AVLN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.